Expanding Horizons for Treatment of Early-Stage Lung Cancer

Lung cancer remains the leading cause of cancer-related death worldwide.1 Even in the context of early-stage disease, survival among patients with lung cancer lags behind that among patients with other common cancers, such as colon, breast, and prostate cancer. The likelihood of 5-year survival remains modest,2 with patients having both local or regional relapse and metastatic relapse. Although surgery with curative intent remains the foundation for management of early-stage lung cancer, these data speak to the urgent need for improvements in systemic control. With the advent of targeted therapies directed against mutant oncoproteins and immune-checkpoint inhibitors to promote host antitumor . . .